Estrella Immunopharma Inc. (ESLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) has a cash flow conversion efficiency ratio of 1.271x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.70 Million) by net assets ($-5.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Estrella Immunopharma Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Estrella Immunopharma Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Estrella Immunopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Estrella Immunopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Estrella Immunopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chih Lien Industrial Co Ltd
TW:2024
|
0.020x |
|
Minehub Technologies Inc
V:MHUB
|
-1.632x |
|
Vraj Iron and Steel Ltd
NSE:VRAJ
|
0.071x |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT3
|
0.033x |
|
German High Street Properties A/S Class B
CO:GERHSP
|
0.009x |
|
K Seng Seng Corporation Bhd
KLSE:5192
|
0.144x |
|
N2N Connect Bhd
KLSE:0108
|
0.055x |
|
Ctac N.V
AS:CTAC
|
-0.292x |
Annual Cash Flow Conversion Efficiency for Estrella Immunopharma Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Estrella Immunopharma Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see ESLA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.37 Million | $-1.79 Million | 0.172x | +100.32% |
| 2024-12-31 | $143.73K | $-7.64 Million | -53.153x | -1313.63% |
| 2023-12-31 | $4.27 Million | $-16.07 Million | -3.760x | -2446.93% |
| 2022-12-31 | $7.07 Million | $-1.04 Million | -0.148x | -110.65% |
| 2021-12-31 | $-1.04 Million | $-1.44 Million | 1.387x | -- |
| 2020-12-31 | $0.00 | $-670.82K | x | -- |
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more